BayBio Startups & Beyond
Area Coordinators: Todd Meyerrose, Glen Bolton, Allan May
BayBio Startups & Beyond:
Name: Tom Ransohoff
Affiliation: BioProcess Technology Consultants
Name: Austin Boesch
Affiliation: Zepteon, Incorporated
Innovations in upstream and downstream bioprocessing have evolved over the years from cell free extracts and new materials for chromatography and membrane based separations, with a focus on selectivity, to novel formats to enable higher throughputs and improve capital efficiency. In order to implement more intensive processes and to ensure product quality objectives are met, the need for specialized modeling software and improved process analytical technologies is increasing. Finally, the move to smaller batch sizes and more specialized drug delivery systems has opened up opportunities in the formulation, fill and finish segment. This session invites entrepreneurs to give technical details of their company's core technologies as well as share their value proposition and rationale for their business model. Investors with insights intowhat they look for in bioprocess companies are also invited. In addition, companies submitting papers can note if they would be interested in participating in a “Shark Tank” type contest.
Name: Steve Flaim
Affiliation: National Heart, Lung and Blood Institutes, NIH
Name: Lucy Lu
Affiliation: Life Science Angels
The pace of discovery of novel medically and commercially relevant technologies in the setting of University laboratories and research-performing institutions is steadily increasing. The desire to capitalize on these discoveries by transitioning them into commercially relevant products that can benefit patients and improve healthcare is gaining momentum. Many such novel technologies are licensed into start-up and early stage companies formed specifically to execute the development and commercialization steps. This session invites papers from start-up and early stage companies seeking to develop and commercialize novel medical and healthcare technologies. Technology sectors will include, but are not limited to, diagnostics, medical devices, biologics and therapeutics. Technologies supporting the promise of personized medicine are encouraged. In addition, companies submitting papers can note if they would be interested in participating in a “Shark Tank” type contest.
Name: Vinod Mahendroo
Affiliation: Life Science Angels
Name: Stuart Gallant
Affiliation: Anthera Pharmaceuticals
With a range of funding sources and virtual services, commercialization of a new discovery has never been easier. And, yet the array of options can be bewildering. This panel discussion will focus on practical hard-won experience obtain by the various types of biotechnology startups. The themes addressed will be:
Panel Discussion 1 80 Minutes:
Funding Sources: Angels, VCs, and Others
Panel Discussion 2 80 minutes: Licensing, Intellectual Property, Regulation, and Reimbursement
Sales Channels, Strategies for Sales Ramp Up
The panel discussions will start with 5-10 minutes of opening remarks where the panelists will describe their backgrounds and provide the insights and advice they would want if they were a founder working on getting an enterprise started. Subsequently, questions from the audience and other panelists will drive a lively discussion.